Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (8): 807-813.doi: 10.3969/j.issn.1000-6621.2020.08.006
• Original Articles • Previous Articles Next Articles
ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao(), PU Jiang()
Received:
2020-06-09
Online:
2020-08-10
Published:
2020-08-10
Contact:
LU Jin-biao,PU Jiang
E-mail:lujinbiao@nifdc.org.cn;pujiang@zhifeishengwu.com
ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC)[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. doi: 10.3969/j.issn.1000-6621.2020.08.006
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.08.006
观察时间 | 空白对照组 (g, $\bar{x}$±s) | 高剂量组 (g, $\bar{x}$±s) | t值a | P值 | 低剂量组 (g,$\bar{x}$±s) | t值a | P值 | 溶剂对照组 (g, $\bar{x}$±s) | t值a | P值 |
---|---|---|---|---|---|---|---|---|---|---|
注射前 | 21.0±1.1 | 20.6±1.3 | 0.571 | 0.575 | 20.5±1.6 | 0.695 | 0.496 | 20.5±1.1 | 0.945 | 0.357 |
注射后1d | 21.3±1.3 | 20.6±1.6 | 1.047 | 0.309 | 21.0±1.6 | 0.453 | 0.656 | 20.2±1.7 | 1.686 | 0.109 |
注射后3d | 21.1±2.1 | 21.3±2.6 | 0.151 | 0.882 | 22.2±2.7 | 0.920 | 0.370 | 20.4±3.0 | 0.682 | 0.504 |
注射后5d | 20.3±2.3 | 20.9±2.8 | 0.570 | 0.576 | 22.2±2.9 | 1.676 | 0.111 | 20.6±3.6 | 0.221 | 0.828 |
注射后7d | 21.6±2.1 | 22.0±2.4 | 0.379 | 0.709 | 23.2±2.8 | 1.462 | 0.161 | 21.6±3.3 | 0.000 | 1.000 |
注射后8d | 22.2±2.1 | 22.6±1.8 | 0.452 | 0.657 | 23.8±2.7 | 1.574 | 0.133 | 22.3±3.5 | 0.108 | 0.915 |
注射后10d | 23.2±2.3 | 23.4±1.6 | 0.189 | 0.852 | 24.5±2.6 | 1.184 | 0.252 | 24.2±3.2 | 0.765 | 0.454 |
注射后12d | 24.4±2.0 | 24.3±2.0 | 0.099 | 0.922 | 25.5±3.0 | 0.933 | 0.363 | 24.7±2.9 | 0.262 | 0.796 |
注射后14d | 25.3±2.3 | 24.9±2.1 | 0.392 | 0.700 | 26.0±3.1 | 0.615 | 0.546 | 25.5±3.1 | 0.145 | 0.886 |
观察时间 | 空白对照组 (g, $\bar{x}$±s) | 高剂量组 (g, $\bar{x}$±s) | t值a | P值 | 低剂量组 (g, $\bar{x}$±s) | t值a | P值 | 溶剂对照组 (g, $\bar{x}$±s) | t值a | P值 |
---|---|---|---|---|---|---|---|---|---|---|
注射前 | 21.2±1.7 | 21.0±1.5 | 0.360 | 0.723 | 20.5±2.1 | 0.900 | 0.380 | 20.8±1.8 | 0.552 | 0.588 |
注射后1d | 21.7±2.5 | 21.2±2.0 | 0.549 | 0.590 | 20.7±2.4 | 0.870 | 0.396 | 20.9±2.4 | 0.767 | 0.453 |
注射后3d | 22.3±3.3 | 21.6±3.1 | 0.543 | 0.594 | 21.6±3.1 | 0.509 | 0.617 | 21.3±2.7 | 0.786 | 0.442 |
注射后5d | 22.2±3.7 | 21.5±3.0 | 0.489 | 0.631 | 22.2±3.2 | 0.006 | 0.995 | 21.5±2.6 | 0.480 | 0.637 |
注射后7d | 22.5±3.5 | 22.2±2.1 | 0.251 | 0.805 | 23.0±3.5 | 0.312 | 0.759 | 22.8±2.5 | 0.214 | 0.833 |
注射后8d | 23.2±3.1 | 22.9±1.9 | 0.305 | 0.764 | 23.3±3.3 | 0.070 | 0.945 | 23.8±2.9 | 0.421 | 0.679 |
注射后10d | 24.3±2.9 | 24.0±2.2 | 0.277 | 0.785 | 23.6±3.9 | 0.433 | 0.670 | 25.2±3.0 | 0.716 | 0.483 |
注射后12d | 25.0±3.0 | 25.0±1.8 | 0.018 | 0.986 | 24.9±3.7 | 0.093 | 0.927 | 25.8±3.4 | 0.531 | 0.602 |
注射后14d | 25.8±3.1 | 26.2±1.9 | 0.318 | 0.754 | 25.8±3.8 | 0.006 | 0.995 | 26.7±3.4 | 0.565 | 0.579 |
致敏情况 | 阴性对照组 (g, $\bar{x}$±s) | 高剂量组 (g, $\bar{x}$±s) | t值a | P值 | 低剂量组 (g, $\bar{x}$±s) | t值a | P值 | 阳性对照组 (g, $\bar{x}$±s) | t值a | P值 |
---|---|---|---|---|---|---|---|---|---|---|
首次 | 329.5±27.4 | 327.5±24.3 | 0.328 | 0.757 | 331.3±26.7 | 0.474 | 0.656 | 328.7±31.8 | 0.215 | 0.838 |
末次 | 348.3±27.0 | 347.2±32.7 | 0.181 | 0.864 | 346.2±32.0 | 0.366 | 0.730 | 336.7±32.2 | 1.860 | 0.122 |
激发 | 399.4±25.4 | 402.2±34.9 | 0.284 | 0.788 | 411.3±38.9 | 0.875 | 0.422 | 383.7±33.3 | 2.069 | 0.093 |
[1] | World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019. |
[2] | World Health Organization. Global tuberculosis report 2018. Geneva:World Health Organization, 2018. |
[3] | World Health Organization. Global strategy and target for tuberculosis prevention, treatment and control after 2015. Geneva:World Health Organization, 2014. |
[4] | 高磊, 金奇. 关口前移结核潜伏感染及其控制. 中国防痨杂志, 2018,40(8):791-795. doi: 10.3969/j.issn.1000-6621.2018.08.003. |
[5] |
Li F, Xu M, Zhou LJ, et al. Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial. Clin Vaccine Immunol, 2016,23(9):767-773. doi: 10.1128/CVI.00154-16.
doi: 10.1128/CVI.00154-16 URL pmid: 27413070 |
[6] | 宫俐, 韩中波. 分子生物学技术在结核病诊断及耐药检测中的应用. 医药前沿, 2018,8(26):69-70. doi: 10.3969/j.issn.2095-1752.2018.26.054. |
[7] |
葛燕萍, 肖和平. γ干扰素释放试验与结核菌素皮肤试验辅助检测肺外结核病的比较. 中国防痨杂志, 2014,36(3):194-197. doi: 10.3969/j.issn.1000-6621.2014.03.011.
doi: 10.3969/j.issn.1000-6621.2014.03.011 URL |
[8] | Lozes E, Huygen K, Content J, et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine, 1997,8(15):830-833. doi: 10.1016/s0264-410x(96)00274-5. |
[9] |
Ravn P, Demissie A, Eguale T, et al. Human T cell reponses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis, 1999,179:637-645. doi: 10.1086/314640.
doi: 10.1086/314640 URL pmid: 9952370 |
[10] |
Ah-Ra J, Green K, Jung J, et al. Hong Mycobacterium tuberculosis ESAT6 Drives the Activation and Maturation of Bone Marrow-Derived Dendritic Cells via TLR4-Mediated Signaling. Immune Netw, 2019,19(2):e13. doi: 10.4110/in.2019.19.e13.
doi: 10.4110/in.2019.19.e13 URL pmid: 31089440 |
[11] |
Dillon DC, Alderson MR, Day CH, et al. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol, 2000,38(9):3285-3290.
doi: 10.1128/JCM.38.9.3285-3290.2000 URL pmid: 10970372 |
[12] |
Harboe M, Oettinger T, Wiker HG, et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virolent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun, 1996,64(1):16-22. doi: 10.1111/j.1749-6632.1996.tb52715.x.
doi: 10.1128/IAI.64.1.16-22.1996 URL pmid: 8557334 |
[1] | Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768. |
[2] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[3] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[4] | DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831. |
[5] | YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. |
[6] | QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879. |
[7] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[8] | ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740. |
[9] | LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488. |
[10] | ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365. |
[11] | ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379. |
[12] | YANG Han,YANG Jing-fen,WU Hao,CUI Xiao-li,DANG Li-yun. Value of MicroDST test in detecting sensitivity of first-line anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 380-384. |
[13] | CHEN Yan-mei,HUANG Xin-chun,SUN Qi,ZHANG Chen-chen,WEN Wen-pei,CHEN Liang. Analysis of drug resistance in patients with smear-negative and culture-positive pulmonary tuberculosis in Guangdong province in 2016 [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 272-275. |
[14] | SUN Jin-xia,ZHANG Qing-wen,LI Yin-hong,JIANG Xin. Study of autophagy induced by myricetin in MTB infected macrophages through PI3K/Akt/mTOR signaling pathway [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 101-107. |
[15] | LIU Bin-bin,GONG Dao-fang,CHEN Zhen-hua,GUO Jing-wei,YU Yan-yan,LIU Feng-ping,OU-Yang hui,TAN Yun-hong. Comparative study on detection rate and detection cost of Mycobacterium tuberculosis complex by three laboratory diagnostic techniques [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 143-148. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||